Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.

Punthakee Z, Hall S, McInnes N, Sherifali D, Tsiplova K, Kirabo FR, Ransom TPP, Harris SB, Lochnan HA, Sigal RJ, Ghosh M, Spaic T, Gerstein HC

Diabetes, obesity & metabolism6 Sept 2024Cited by 6 (Europe PMC)

PMID39239702DOI10.1111/dom.15926PepBankPUB-39239702

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, a 16-week intensive regimen with coaching, metformin and fixed-ratio insulin degludec/liraglutide gave lower HbA1c than standard care.
In plain wordsIn adults with type 2 diabetes, an intensive regimen that included insulin degludec/liraglutide gave lower HbA1c than standard care.
Peptide
Liraglutide
Outcome
DecreaseHbA1c at end of 16-week intervention
Study
n = 159
Comparator
Standard care
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
40 mmol/mol
intervention
HbA1c
51 mmol/mol
control
Source sentences
Summary
intervention participants achieved lower HbA1c levels (40 ± 4 vs. 51 ± 7 mmol/mol; p < 0.0001)
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre open-label randomized controlled trial, insulin-naïve participants within 5 years of diabetes diagnosis were assigned to a 16-week remission intervention regimen or standard care, and followed for relapse of diabetes and sustained remission for an additional year after stopping glucose-lowering drugs.
Summary · context
A total of 159 participants aged 57 ± 10 years, with diabetes duration 2.6 ± 1.5 years, body mass index 33.5 ± 6.5 kg/m², and glycated haemoglobin (HbA1c) level 53 ± 7 mmol/mol were randomized and analysed (79 intervention, 80 control).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3923970201
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, a 16-week intensive regimen with coaching, metformin and fixed-ratio insulin degludec/liraglutide gave more weight loss than standard care.
In plain wordsIn adults with type 2 diabetes, an intensive regimen that included insulin degludec/liraglutide led to more weight loss than standard care.
Peptide
Liraglutide
Outcome
IncreaseWeight loss at end of 16-week intervention
Study
n = 159
Comparator
Standard care
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
3.3%
intervention
Weight loss
1.9%
control
Source sentences
Summary
lost more weight (3.3 ± 4.4% vs. 1.9 ± 3.0%; p = 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre open-label randomized controlled trial, insulin-naïve participants within 5 years of diabetes diagnosis were assigned to a 16-week remission intervention regimen or standard care, and followed for relapse of diabetes and sustained remission for an additional year after stopping glucose-lowering drugs.
Summary · context
A total of 159 participants aged 57 ± 10 years, with diabetes duration 2.6 ± 1.5 years, body mass index 33.5 ± 6.5 kg/m², and glycated haemoglobin (HbA1c) level 53 ± 7 mmol/mol were randomized and analysed (79 intervention, 80 control).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3923970202
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the regimen with fixed-ratio insulin degludec/liraglutide lowered the hazard of diabetes relapse overall versus standard care, but not over time.
In plain wordsIn adults with type 2 diabetes, an intensive regimen that included insulin degludec/liraglutide lowered relapse risk overall, but this was not sustained over time.
Peptide
Liraglutide
Outcome
DecreaseDiabetes relapse hazard over 1 year
Study
n = 159
Comparator
Standard care
Outcome group
Glycemic control · Metabolic and weight
Measurements
Hazard ratio
0.63
relapse, intervention vs control
Source sentences
Summary
There was a lower hazard of diabetes relapse overall in the intervention group compared to controls (hazard ratio 0.63, 95% confidence interval [CI] 0.45, 0.88; p = 0.007), although this was not sustained over time.
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre open-label randomized controlled trial, insulin-naïve participants within 5 years of diabetes diagnosis were assigned to a 16-week remission intervention regimen or standard care, and followed for relapse of diabetes and sustained remission for an additional year after stopping glucose-lowering drugs.
Summary · context
A total of 159 participants aged 57 ± 10 years, with diabetes duration 2.6 ± 1.5 years, body mass index 33.5 ± 6.5 kg/m², and glycated haemoglobin (HbA1c) level 53 ± 7 mmol/mol were randomized and analysed (79 intervention, 80 control).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3923970203
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, remission rates at 12 weeks after the regimen with fixed-ratio insulin degludec/liraglutide were not significantly higher than with standard care.
In plain wordsIn adults with type 2 diabetes, an intensive regimen that included insulin degludec/liraglutide did not significantly raise remission rates at 12 weeks.
Peptide
Liraglutide
Outcome
No significant changeDiabetes remission at 12 weeks after intervention
Study
n = 159
Comparator
Standard care
Outcome group
Glycemic control · Metabolic and weight
Measurements
Remission rate
17.7%
intervention
Remission rate
12.5%
control
Source sentences
Summary
Remission rates in the intervention group were not significantly higher than in the control group at 12 weeks (17.7% vs. 12.5%, relative risk [RR] 1.42, 95% CI 0.67, 3.00; p = 0.36)
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre open-label randomized controlled trial, insulin-naïve participants within 5 years of diabetes diagnosis were assigned to a 16-week remission intervention regimen or standard care, and followed for relapse of diabetes and sustained remission for an additional year after stopping glucose-lowering drugs.
Summary · context
A total of 159 participants aged 57 ± 10 years, with diabetes duration 2.6 ± 1.5 years, body mass index 33.5 ± 6.5 kg/m², and glycated haemoglobin (HbA1c) level 53 ± 7 mmol/mol were randomized and analysed (79 intervention, 80 control).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3923970204
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, remission rates at 52 weeks after the regimen with fixed-ratio insulin degludec/liraglutide were not significantly higher than with standard care.
In plain wordsIn adults with type 2 diabetes, an intensive regimen that included insulin degludec/liraglutide did not significantly raise remission rates at 52 weeks.
Peptide
Liraglutide
Outcome
No significant changeDiabetes remission at 52 weeks after intervention
Study
n = 159
Comparator
Standard care
Outcome group
Glycemic control · Metabolic and weight
Measurements
Remission rate
6.3%
intervention
Remission rate
3.8%
control
Source sentences
Summary
Remission rates in the intervention group were not significantly higher than in the control group at 12 weeks (17.7% vs. 12.5%, relative risk [RR] 1.42, 95% CI 0.67, 3.00; p = 0.36) or at 52 weeks (6.3% vs. 3.8%, RR 1.69, 95% CI 0.42, 6.82)
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre open-label randomized controlled trial, insulin-naïve participants within 5 years of diabetes diagnosis were assigned to a 16-week remission intervention regimen or standard care, and followed for relapse of diabetes and sustained remission for an additional year after stopping glucose-lowering drugs.
Summary · context
A total of 159 participants aged 57 ± 10 years, with diabetes duration 2.6 ± 1.5 years, body mass index 33.5 ± 6.5 kg/m², and glycated haemoglobin (HbA1c) level 53 ± 7 mmol/mol were randomized and analysed (79 intervention, 80 control).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3923970205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.